Table 3

Predictive factors for composite reversion after HBsAg seroclearance

Univariate analysisMultivariable analysis*
VariablesHR95% CIp ValueHR95% CIp Value
Age1.041.00 to to 1.090.14
Gender (male)1.710.49 to 5.900.40
HBeAg positivity1.730.65 to 4.610.28
HBV DNA level (log10 IU/mL)1.140.87 to 1.500.33
ALT ≥ 40 IU/L1.560.21 to 11.70.67
Cirrhosis1.680.63 to 4.470.30
Selection for drug-resistance HBV mutants†0.730.24 to 2.220.58
Duration of treatment (months)0.990.97 to to 1.010.23
Anti-HBs seroconversion during follow-up0.180.02 to 0.800.020.210.02 to 0.890.03
  • Composite reversion was defined as virological reversion and/or HBsAg reversion.

  • Predictive factors are at the initiation of antiviral therapy unless specified.

  • Total number of patients, 110; event (composite reversion) number, 18.

  • Extended Cox proportional hazards model for time-dependent covariate (anti-HBs seroconversion).

  • *Multivariable analysis including variables with p<0.25 at univariate analysis.

  • †During antiviral therapy before HBsAg seroclearance.

  • ALT, alanine aminotransferase.